Intellia Therapeutics, Inc. filed a Form 8-K on September 4, 2026, disclosing that it entered into a senior secured credit agreement with OrbiMed Royalty & Credit Opportunities V, LP as administrative agent, providing access to up to $400 million in debt financing.

Key Highlights

  • Facility size: The credit facility provides up to $400 million in total potential capacity across multiple tranches.
  • Initial draw: $75 million was drawn on the closing date of September 4, 2026.
  • Maturity date: The credit facility matures on September 4, 2031, with the full outstanding principal due at that time.
  • Interest rate: Loans bear interest at the greater of 3.00% or one-month SOFR, plus an applicable margin of 6.15%, payable monthly.
  • Collateral: All obligations are secured on a first-priority basis by substantially all assets of the company, including its intellectual property.
  • Liquidity covenant: The company must maintain at least $50 million in controlled accounts until the FDA approves the BLA for lonvoguran ziclumeran.
  • Lenders: OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities V, LP are the initial lenders.

Intellia Draws $75 Million Under New Five-Year OrbiMed Credit Agreement

According to the filing, Intellia Therapeutics (NASDAQ:NTLA) entered into the Credit Agreement on September 4, 2026, structuring the facility across five potential tranches. Beyond the $75 million drawn at closing, the company disclosed that an additional $75 million may be drawn at its option upon FDA approval of its biologics license application for lonvoguran ziclumeran ("lonvo-z") prior to a certain date. Three additional $40 million draws are available upon achieving certain revenue targets for lonvo-z prior to certain dates, and a further $30 million draw is available upon achieving an equity fundraising target prior to a certain date. An uncommitted incremental facility of up to $100 million is also available, subject to mutual agreement among the company and the lenders.

The filing states that proceeds will be used for "working capital needs and general corporate purposes." The company reported that it may elect to prepay all or any portion of amounts owed prior to the maturity date, subject to a repayment premium or exit fee, as applicable, as well as accrued interest on the amount repaid or prepaid. Mandatory prepayments are also required under certain circumstances, including proceeds from indebtedness, certain asset sales, and casualty events.

The Credit Agreement contains negative covenants that, subject to certain exceptions, restrict the company's ability to incur additional indebtedness, grant liens, make investments including acquisitions, effectuate mergers or consolidations, engage in asset sales and licensing transactions, pay dividends, and undertake other matters. The filing noted that an exception exists allowing the company to enter synthetic royalty transactions, subject to certain restrictions. The filing also identifies several events of default, including payment defaults, covenant defaults, bankruptcy and insolvency proceedings, cross-defaults, judgments, and change of control. The company's press release described the facility as "non-dilutive," as disclosed in Item 7.01. Forward-looking statements in the filing are the company's own and are subject to its cautionary language and identified risk factors.

What Was Disclosed

Intellia Therapeutics disclosed entry into a five-year, up to $400 million senior secured credit facility with OrbiMed as administrative agent, with $75 million drawn at closing, structured interest rates, multiple conditional draw tranches, and customary financial and negative covenants.